NEW YORK, July 8, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Revolution Medicines, Inc. (NASDAQ: RVMD) on behalf of the company's shareholders. The investigation seeks to determine whether Revolution Medicines's directors breached their fiduciary duties in connection with recent corporate actions. If you are a shareholder of Revolution Medicines, Inc. and are interested in obtaining additional information regarding your rights and options, free of charge, please visit us ...

Revolution Medicines, Inc. (NASDAQ:RVMD) Q1 2024 Results Conference Call May 8, 2024 4:30 PM ET Company Participants Erin Graves - Senior Director, Corporate Communications and Investor Relations Dr. Mark Goldsmith - Chairman and Chief Executive Officer Jack Anders - Chief Financial Officer Dr. Steve Kelsey - President of R&D Dr. Wei Lin - Chief Medical Officer Conference Call Participants Marc Frahm - TD Cowen Michael Schmidt - Guggenheim Securities Eric Joseph - JPMorgan Jonathan Chang - Leerink Partners ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number: 001-39219 Revolution Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 47-2029180 | | --- | ...

Exhibit 99.1 Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate Progress Revolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., May 8, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2024, and provided an update on corporate progress. The comp ...

Revolution Medicines, Inc. (NASDAQ:RVMD) Q4 2023 Earnings Conference Call February 26, 2024 4:30 PM ET Company Participants Erin Graves - Senior Director, Corporate Communications and Investor Relations Mark Goldsmith - Chairman and Chief Executive Officer Jack Anders - Chief Financial Officer Wei Lin - Chief Medical Officer Conference Call Participants Ernie Rodriguez - TD Cowen Michael Smith - Guggenheim Partners Eric Joseph - JP Morgan Jonathan Chang - Leerink Partners Ellie Merle - UBS Ami Fadia - Needh ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 For the fiscal year ended December 31, 2023 OR FORM 10-K (Mark One) Revolution Medicines, Inc. (Exact name of Registrant as specified in its Charter) | Delaware | 47-2029180 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | 700 Saginaw Drive | | | Redwood City, CA | 94063 ...

November 6, 2023 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, availability of funding, ability to manage existing collaborations and establish new strategic collaborations, licensing or other arrangements, the scope, ...

Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ET Company Participants Erin Graves - Senior Director of Corporate Communications and IR Mark Goldsmith - Chairman and CEO Jack Anders - CFO Steve Kelsey - President of Research & Development Conference Call Participants Marc Frahm - TD Cowen Eric Joseph - JPMorgan Jonathan Chang - Leerink Partners Ami Fadia - Needham Alec Stranahan - Bank of America Operator Good day, and thank you for standing by. Welcome to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___ to ___ Commission File Number: 001-39219 Revolution Medicines, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-2029180 (State or ...

Revolution Medicines, Inc. (NASDAQ:RVMD) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Erin Graves – Senior Director of Corporate Communications and Investor Relations Mark Goldsmith – Chairman and Chief Executive Officer Jack Anders – Chief Financial Officer Steve Kelsey – President of Research & Development Conference Call Participants Marc Frahm – TD Cowen Faisal Khushid – Leerink Partners Jay Olson – Oppenheimer Ami Fadia – Needham Alec Stranahan – Bank of America Ben B ...